A Phase 3 interventional study of insulin degludec/insulin aspart and insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 40 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-03-21.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 61st largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 33rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 350th largest by enrollment of the 428 interventional ones that give a count, is one of 33 that started in 2013, is one of 187 in phase 3, and was the 335th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of the trial is to compare efficacy of insulin degludec/insulin aspart (IDegAsp) twice daily (BID) + insulin aspart (IAsp) once daily (OD) versus basal bolus with insulin degludec (IDeg) OD + IAsp three times a day (TID) in controlling glycaemia by evaluating glycosylated haemoglobin (HbA1c). The trial is an extension to trial NN5401-3941 (NCT01680341).
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 40 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/insulin aspart · Drug: insulin aspart
Drug: insulin degludec · Drug: insulin aspart
Drug pages: Insulin degludec · Insulin Aspart
For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Change from baseline in HbA1c after 26 weeks of treatment
Time frame: Week 0, week 26
Incidence of Treatment Emergent Adverse Events (TEAEs)
A treatment emergent adverse event was defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last dose of the trial product.
Time frame: During 26 weeks of treatment
Number of Treatment Emergent Hypoglycaemic Episodes
Confirmed hypoglycaemic episodes were defined as episodes that are either: * severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or * biochemically confirmed by a PG value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.
Time frame: During 26 weeks of treatment
Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes
Hypoglycaemic episodes were defined as nocturnal if the time of onset was between 00:01 and 05:59 hours inclusive. Confirmed hypoglycaemic episodes were defined as severe hypoglycaemic episodes and/or a measured PG below 3.1 mmol/L (below 56 mg/dL).
Time frame: During 26 weeks of treatment
Change From Baseline in Fasting Plasma Glucose (FPG)
Change from baseline in FPG after 26 weeks of treatment. FPG was analysed on blood samples from fasting subjects which were analysed centrally.
Time frame: Week 0, week 26
The trial was conducted at 20 sites in 4 countries as follows: Germany: 1 site; Malaysia: 2 sites; Turkey: 1 site; United States: 16 sites. The subjects in this trial were to continue from trial NN5401-3941 (NCT01680341).
| Milestone | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID |
|---|---|---|
| Started | 20 | 20 |
| Completed | 15 | 15 |
| Not completed | 5 | 5 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Physician decision | 1 | 1 |
| Withdrew: Unclassified | 2 | 1 |
Change from baseline in HbA1c after 26 weeks of treatment
| percentage of glycosylated haemoglobin | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID |
|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) | 0.05 ± 0.20 | -0.49 ± 0.19 |
A treatment emergent adverse event was defined as an event that had onset date on or after the first day of trial product administration, and no later than 7 days after the last dose of the trial product.
| number of events | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID |
|---|---|---|
| Incidence of Treatment Emergent Adverse Events (TEAEs) | 33 | 45 |
Confirmed hypoglycaemic episodes were defined as episodes that are either: * severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or * biochemically confirmed by a PG value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.
| episodes | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID |
|---|---|---|
| Number of Treatment Emergent Hypoglycaemic Episodes | 54 | 95 |
Hypoglycaemic episodes were defined as nocturnal if the time of onset was between 00:01 and 05:59 hours inclusive. Confirmed hypoglycaemic episodes were defined as severe hypoglycaemic episodes and/or a measured PG below 3.1 mmol/L (below 56 mg/dL).
| episodes | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID |
|---|---|---|
| Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes | 13 | 12 |
Change from baseline in FPG after 26 weeks of treatment. FPG was analysed on blood samples from fasting subjects which were analysed centrally.
| mmol/L | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID |
|---|---|---|
| Change From Baseline in Fasting Plasma Glucose (FPG) | -0.80 ± 3.59 | -2.57 ± 2.73 |
Collected over Adverse events were captured on the onset date on or after the first day of exposure to randomised treatment and no later than the last day of randomised treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDeg OD + IAsp TID | — | 2/20 (10%) | 16/20 (80%) |
| IDegAsp BID + IAsp OD | — | 2/20 (10%) | 15/20 (75%) |
| Event | IDeg OD + IAsp TID | IDegAsp BID + IAsp OD |
|---|---|---|
| Atrial fibrillationCardiac disorders | 0/20 | 1/20 |
| Peptic ulcer haemorrhageGastrointestinal disorders | 1/20 | 0/20 |
| Cerebrovascular accidentNervous system disorders | 1/20 | 0/20 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/20 | 1/20 |
| CholecystectomySurgical and medical procedures | 1/20 | 0/20 |
| Event | IDeg OD + IAsp TID | IDegAsp BID + IAsp OD |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/20 | 1/20 |
| PyrexiaGeneral disorders | 4/20 | 1/20 |
| Diabetic retinopathyEye disorders | 0/20 | 3/20 |
| Abdominal pain upperGastrointestinal disorders | 2/20 | 1/20 |
| FatigueGeneral disorders | 0/20 | 2/20 |
| Oedema peripheralGeneral disorders | 0/20 | 2/20 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/20 | 1/20 |
| LymphadenopathyBlood and lymphatic system disorders | 1/20 | 0/20 |
| CataractEye disorders | 0/20 | 1/20 |
| Eye swellingEye disorders | 1/20 | 0/20 |
Full analysis set (FAS) included all randomised subjects.
| Age, Continuous(years) | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID | Total |
|---|---|---|---|
| Mean | 58.0 ± 8.0 | 56.9 ± 8.1 | 57.5 ± 8.0 |
| Sex: Female, Male(Participants) | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID | Total |
|---|---|---|---|
| Female | 5 | 9 | 14 |
| Male | 15 | 11 | 26 |
| Glycosylated haemoglobin (HbA1c)(percentage of glycosylated haemoglobin) | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID | Total |
|---|---|---|---|
| Mean | 7.9 ± 0.7 | 7.7 ± 0.6 | 7.8 ± 0.7 |
| Fasting plasma glucose (FPG)(mmol/L) | IDegAsp BID + IAsp OD | IDeg OD + IAsp TID | Total |
|---|---|---|---|
| Mean | 7.3 ± 3.5 | 8.6 ± 2.8 | 7.9 ± 3.2 |
The record gives a start of Mar 2013, a primary completion of Mar 2014 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 8 months after primary completion. A results delay was requested in Nov 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Insulin Aspart